Key data lift Novo Nordisk's hope of making semaglutide a new standard of care in diabetes
Shares in diabetes giant Novo Nordisk (NOV: N) are up nearly 3% in Copenhagen this morning, on the news of positive data from the Phase III SUSTAIN 7 trial.
The Danish firm is conducting the trial to compare its once-weekly diabetes drug semaglutide with rival GLP-1 therapy dulaglutide, which is marketed by Eli Lilly (NYSE: LLY) as Trulicity. Both were tested as adjuncts to standard-of-care metformin.
In the 40-week trial involving type 2 diabetes patients, the company says that the lower dose of 0.5mg achieved a reduction of 1.5% compared with a reduction of 1.1% with 0.75mg dulaglutide.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze